Black race and CA 19-9 nonproduction is associated with limited pathologic response to neoadjuvant chemotherapy in patients with localized pancreatic cancer

被引：0
|
作者：
Martos, Mary P.
Dickey, Erin M.
Abdilleh, Kawther
Ahmad, Syed A.
Maithel, Shishir K.
Hammill, Chet W.
Kim, Hong Jin
Abbott, Daniel E.
Kooby, David A.
Parikh, Alexander A.
Hosein, Peter J.
Merchant, Nipun B.
Datta, Jashodeep
Hester, Caitlin A.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 17期
关键词：
D O I：
10.1158/1538-7445.PANCREATIC24-A019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A019
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CA 19-9 as a predictor for the response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy
    Koom, W.
    Seong, J.
    Kim, Y.
    Pyun, H.
    Song, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S261 - S262
  • [22] Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer
    Stephanie E. Combs
    Daniel Habermehl
    Kerstin A. Kessel
    Frank Bergmann
    Jens Werner
    Patrick Naumann
    Dirk Jäger
    Markus W. Büchler
    Jürgen Debus
    Annals of Surgical Oncology, 2014, 21 : 2801 - 2807
  • [23] Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer
    Combs, Stephanie E.
    Habermehl, Daniel
    Kessel, Kerstin A.
    Bergmann, Frank
    Werner, Jens
    Naumann, Patrick
    Jaeger, Dirk
    Buechler, Markus W.
    Debus, Juergen
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (08) : 2801 - 2807
  • [24] CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
    Hess, Viviane
    Glimelius, Bengt
    Grawe, Philipp
    Dietrich, Daniel
    Bodoky, Gyoergy
    Ruhstaller, Thomas
    Bajetta, Emilio
    Saletti, Piercarlo
    Figer, Arie
    Scheithauer, Werner
    Herrmann, Richard
    LANCET ONCOLOGY, 2008, 9 (02): : 132 - 138
  • [25] CA 19-9: Not a magic marker for pancreatic cancer
    Daram, Sumanth R.
    SOUTHERN MEDICAL JOURNAL, 2006, 99 (03) : 205 - 205
  • [26] CA 19-9 and Lewis Antigens in Pancreatic Cancer
    Atkins, Carl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2572 - 2573
  • [27] Is CA 19-9 useful in the management of pancreatic cancer?
    Balzano, Gianpaolo
    Di Carlo, Valerio
    LANCET ONCOLOGY, 2008, 9 (02): : 89 - 91
  • [28] Exploiting the relevance of CA 19-9 in pancreatic cancer
    Salleh, Syaza
    Thyagarajan, Anita
    Sahu, Ravi P.
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2020, 6
  • [29] CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer
    Willett, CG
    Daly, WJ
    Warshaw, AL
    AMERICAN JOURNAL OF SURGERY, 1996, 172 (04): : 350 - 352
  • [30] Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival
    Heger, Ulrike
    Sun, Huihui
    Hinz, Ulf
    Klaiber, Ulla
    Tanaka, Masayuki
    Liu, Bing
    Sachsenmaier, Milena
    Springfeld, Christoph
    Michalski, Christoph W.
    Buechler, Markus W.
    Hackert, Thilo
    HPB, 2020, 22 (02) : 224 - 232
12345